Sulfasalazine

SKU: orb1310181

Description

Sulfasalazine is a prodrug derived from salicylic acid that exhibits affinity for elastin-rich tissues. It is widely used in research to study ferroptosis and inflammatory pathways, as it inhibits NF-κB, TGF-β, and COX-2 in both cellular and animal models of disease.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 599-79-1
• MW: 398.39
• Purity: >98%
• Formula: C₁₈H₁₄N₄O₅S
• SMILES: OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
• Target: Glutathione
• Solubility: Soluble in DMSO (up to 25 mg/ml).

Bioactivity

• Target IC50:
  Synthesis of leukotriene B4:250 μM|PAF:50 µM|Cystine uptake:24.7 ± 5.6 μM|Synthesis of 5-hydroxyeicosatetraenoic acid:250 μM|contractile leukotriene activity:0.15 mM|Synthesis of leukotriene C4:100 μM|synthesis of LTB4:2.8 mM (endogenous arachidonic acid is the substrate)|synthesis of LTB4:0.8 mM (exogenous arachidonic acid is the substrate)
• In Vivo:
  METHODS: To detect antitumor activity in vivo, Sulfasalazine (250 mg/kg) was administered intraperitoneally to C57BL/6N mice bearing B16F10 xenografts once daily for three days. Twenty-four hours after the third Sulfasalazine dose, local X-ray irradiation was applied to anesthetized tumor-bearing C57BL/6N mice at a dose of 4 Gy. RESULTS: Sulfasalazine alone did not significantly inhibit tumor growth; X-ray irradiation partially reduced tumor growth; the combination of Sulfasalazine and X-rays synergistically reduced tumor growth.
• In Vitro:
  METHODS: Rat glioma cells F98 and human glioma cells U251 were treated with Sulfasalazine (200-400 µM) for 96 h. Cell viability was measured by MTT assay. RESULTS: Cell viability was significantly reduced in F98 at 200-400 µM Sulfasalazine concentration and U251 showed reduced cell viability at 400 µM Sulfasalazine. METHODS: Mouse melanoma cells B16F10 and mouse embryonic fibroblasts MEF were treated with Sulfasalazine (10-1000 µM) for 24 h. Cellular ROS levels were measured by DCFDA staining. RESULTS: At lower Sulfasalazine concentrations (10-100 µM), no increase in intracellular ROS was observed. At higher concentrations of Sulfasalazine (800-1000 µM), there was an approximately 2.3-fold increase in intracellular ROS in B16F10 cells, while no increase in ROS was observed in MEF cells.
• Cell Research:
  Sulfasalazine is dissolved in culture medium. SW620 cells are grown in Dulbecco's modified Eagle medium, supplemented with 10% heat-inactivated FCS, 2 mmol/liter glutamine, and 1% (wt/vol) penicillin/streptomycin. SW620 cells are transfected with the 3xIgkBLuc reporter construct. After 18 h, cells are incubated with either medium alone or with sulfasalazine (0.1, 0.2, 0.5, 1, 2, 5 mM) before stimulation with TNFα, LPS, or PMA. Luciferase assay is performed.

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

COX-2, COX-1, Apoptosis, Antibiotic, Bacterial, Azulfidine, Autophagy, NSC 667219, inhibit, Nuclear factor-κB, Nuclear factor-kappaB, NSC667219, NSC-667219, NF-κB, NFκB, NFkB, NF-kB, Ferroptosis, Inhibitor, Sulfasalazine

Compound Identifiers

PubChem CID

5339